What is Hemostasis?
Hemostasis, LLC operates at the intersection of biotechnology and surgical instrumentation, specializing in the design and manufacture of high-performance hemostatic dressings and intranasal splints. By leveraging proprietary chitosan formulations, the company has developed flagship brands such as PosiSep and NexStat, which are engineered to optimize patient outcomes in complex clinical environments. Through collaborative development cycles with leading physicians, Hemostasis, LLC has successfully transitioned from a niche developer to a critical supplier for hospital and surgical care facilities globally. Their market position is defined by a commitment to clinical efficacy and the integration of advanced materials science into everyday medical practice, ensuring that their devices meet the rigorous demands of modern trauma and surgical intervention.
How much funding has Hemostasis raised?
Hemostasis has raised a total of $864K across 2 funding rounds:
Debt
$350K
Debt
$514K
Debt (2020): $350K with participation from PPP
Debt (2021): $514K led by PPP
Key Investors in Hemostasis
PPP
Public-Private Partnership
What's next for Hemostasis?
With the recent influx of capital, Hemostasis, LLC is well-positioned to accelerate its global expansion and deepen its research and development pipeline. The company is expected to focus on scaling its manufacturing capabilities to meet the rising demand for its specialized medical devices while simultaneously exploring new applications for its proprietary chitosan technology. As the firm moves into this next phase of growth, strategic priorities will likely include strengthening its distribution networks in international markets and pursuing further clinical validation for its product portfolio. By maintaining its focus on physician-led innovation, Hemostasis, LLC aims to set new benchmarks in bleeding control, ultimately enhancing the standard of care for patients undergoing surgical procedures worldwide.
See full Hemostasis company page
